文献速递糖尿病

短期SGLT2抑制期间胰高血糖素水平主要由血糖变化调控

Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

该研究为4期单中心随机三治疗交叉开放标签研究,纳入15例二甲双胍治疗的2型糖尿病患者,评估达格列净单次给药联合等血糖钳夹、生理盐水或沙格列汀后胰高血糖素等变化。结果显示等血糖钳夹组胰高血糖素及脂质动员指标低于生理盐水组,血糖变化是胰高血糖素变化的主要预测因素。

要点

  • 等血糖钳夹组胰高血糖素、胰高血糖素/胰岛素比值及NEFA、甘油、β-羟丁酸均低于生理盐水组。
  • 多变量分析中血糖水平变化是胰高血糖素水平变化的主要预测因素。
  • 沙格列汀组胰高血糖素和活性GLP-1高于生理盐水组,但血糖和胰岛素无差异。

核心结论

  • 短期SGLT2抑制期间血糖下降程度显著促进胰高血糖素和胰岛素分泌的调控及脂质动员。

研究设计与样本

  • 4期、单中心、随机、三治疗交叉、开放标签研究,纳入15例接受二甲双胍治疗的2型糖尿病患者。

主要发现

  • 等血糖钳夹组血糖和胰岛素稳定,生理盐水组下降(P for difference < 0.001)。
  • 等血糖钳夹组胰高血糖素/胰岛素比值(Pdiff < 0.001)、胰高血糖素(Pdiff < 0.01)、非酯化脂肪酸(Pdiff < 0.01)、甘油(Pdiff < 0.01)和β-羟丁酸(Pdiff < 0.05)均低于生理盐水组。
  • 多变量分析中血糖水平变化是胰高血糖素水平变化的主要预测因素。
  • 沙格列汀组胰高血糖素和活性GLP-1水平高于生理盐水组,但血糖和胰岛素水平无差异。
  • 口服葡萄糖耐量试验期间,沙格列汀组较生理盐水组血糖升高更少、胰高血糖素下降更多。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The mechanism mediating sodium glucose cotransporter-2 (SGLT2) inhibitor-associated increase in glucagon levels is unknown. OBJECTIVE: To assess short-term effects on glucagon, other hormones, and energy substrates after SGLT2 inhibition and whether such effects are secondary to glucose lowering. The impact of adding a dipeptidyl peptidase-4 inhibitor was addressed. DESIGN, SETTING, AND PATIENTS: A phase 4, single-center, randomized, three-treatment crossover, open-label study including 15 patients with type 2 diabetes treated with metformin. INTERVENTIONS: Patients received a single-dose of dapagliflozin 10 mg accompanied by the following in randomized order: isoglycemic clamp (experiment DG); saline infusion (experiment D); or saxagliptin 5 mg plus saline infusion (experiment DS). Directly after 5-hour infusions, a 2-hour oral glucose tolerance test (OGTT) was performed. RESULTS: Glucose and insulin levels were stable in experiment DG and decreased in experiment D [P for difference (Pdiff) < 0.001]. Glucagon-to-insulin ratio (Pdiff < 0.001), and levels of glucagon (Pdiff < 0.01), nonesterified fatty acids (Pdiff < 0.01), glycerol (Pdiff < 0.01), and β-OH-butyrate (Pdiff < 0.05) were lower in DG vs D. In multivariate analysis, change in glucose level was the main predictor of change in glucagon level. In DS, glucagon and active GLP-1 levels were higher than in D, but glucose and insulin levels did not differ. During OGTT, glucose levels rose less and glucagon levels fell more in DS vs D. CONCLUSION: The degree of glucose lowering markedly contributed to regulation of glucagon and insulin secretion and to lipid mobilization during short-term SGLT2 inhibition.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lundkvist P, Pereira MJ, Kamble PG, et al. Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2019. PMID: 30137410. doi:10.1210/jc.2018-00969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。